Ashton Thomas Securities LLC Buys New Holdings in Pfizer Inc. (NYSE:PFE)

Ashton Thomas Securities LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 6,843 shares of the biopharmaceutical company’s stock, valued at approximately $198,000.

Several other large investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Pfizer during the first quarter worth approximately $315,000. GSA Capital Partners LLP bought a new position in Pfizer in the first quarter valued at approximately $439,000. Cozad Asset Management Inc. increased its stake in Pfizer by 12.9% in the first quarter. Cozad Asset Management Inc. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,216,000 after acquiring an additional 5,005 shares during the last quarter. Koshinski Asset Management Inc. increased its stake in Pfizer by 20.5% in the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 4,130 shares during the last quarter. Finally, WP Advisors LLC increased its stake in Pfizer by 53.9% in the first quarter. WP Advisors LLC now owns 65,241 shares of the biopharmaceutical company’s stock valued at $1,810,000 after acquiring an additional 22,844 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Trading Down 1.8 %

PFE opened at $26.24 on Tuesday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The company has a market cap of $148.70 billion, a P/E ratio of 35.46, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. The company has a fifty day moving average price of $28.89 and a two-hundred day moving average price of $28.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) earnings per share. Analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.40%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.